MDM2 and neoplasm: Subgroup analyses for evaluable patients with sufficient tumour samples for NGS from PROFILE-1001 and phase II trial of savolitinib and NGS analyses from liquid biopsies from the VISION trial showed that patients with METex14 NSCLC could have concomitant gene mutations and that the most common are p53 (38–49%), MDM2 (20–25%), and CDKN2A (20%) [68,84,93].